ClinicalTrials.gg
CompletedNCT01683266EDITION IVUpdated Jun 24, 2015Results posted

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus

A Phase 3 interventional study of HOE901-U300 (Insulin glargine new formulation) and Lantus (Insulin glargine) in Type 1 Diabetes Mellitus, sponsored by Sanofi. Completed at 147 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-24.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
549
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.

Enrollment
3rd of 66
549 · median 73
Started
2012
with 7 others
Phase 3
18 of 66
none open now
Registered
39th of 66
by date
Lead sponsor
24 of 66
Sanofi

Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 3rd largest by enrollment, is one of 8 that started in 2012, is one of 18 in phase 3, and was the 39th registered.

Diabetes Mellitus, Type 1

3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

Primary Objective:

  • To compare the efficacy of a new formulation of insulin glargine and Lantus (overall, regardless the injection time) in terms of change of HbA1c from baseline to endpoint (scheduled Month 6) in participants with type 1 diabetes mellitus

Secondary Objective:

  • To compare HOE901-U300 and Lantus when given in the morning or in the evening in terms of:
  • Change of HbA1c from baseline to endpoint (scheduled Month 6)
  • Change from baseline to endpoint (Month 6) in fasting plasma glucose (FPG), plasma glucose prior to injection of study drug, plasma glucose at 03:00 hours, mean plasma glucose (8-point profiles), glucose variability, treatment satisfaction and health related quality of life in participants with Type 1 Diabetes Mellitus (T1DM)
  • Reaching target HbA1c values and controlled plasma glucose (all and reaching target without hypoglycemia)
  • Frequency of occurrence and diurnal distribution of hypoglycemia by category of hypoglycemia (symptomatic, asymptomatic, nocturnal, severe, probable and relative)
  • Safety and tolerability of HOE901-U300 including development of anti-insulin antibody (AIAs) during the 12-month study period
Read the detailed description

The maximum study duration was up to approximately 54 weeks per participants:

  • Up to 2-week screening period
  • 6-month open-label comparative efficacy and safety treatment period
  • 6-month open-label comparative safety extension period
  • 48-hour post-treatment safety follow-up period
03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants with type 1 diabetes mellitus

Exclusion criteria

Exclusion criteria:

  • less than (\<) 7.0% (53 mmol/mol) or greater than (>) 10% (86 mmol/mol) at screening
  • Less than 1 year on any basal plus mealtime insulin and self-monitoring of blood glucose before screening visit
  • Participants not on stable insulin dose (+/-20 percent total basal insulin dose) in the last 30 days prior to screening visit
  • Participants using pre-mix insulins, human regular insulin as mealtime insulin and/or any glucose-lowering drugs other than basal insulin and mealtime analogue insulin in the last 3 months before screening visit
  • Use of an insulin pump in the last 6 months before screening visit and no plan to switch to insulin pump in the next 12 months
  • Not willing to inject insulin glargine as assigned by the randomization process once daily in the morning or evening;
  • Severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic ketoacidosis in the last 6 months before screening visit
  • Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (example laser, surgical treatment or injectable drugs) during the study period

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
549 participants (actual)

Study arms

  • Experimental
    HOE901-U300

    HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]).

    Drug: HOE901-U300 (Insulin glargine new formulation)

  • Active comparator
    Lantus

    Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).

    Drug: Lantus (Insulin glargine)

Interventions

06

What researchers measure

Primary outcomes

  1. Change In HbA1c From Baseline to Month 6 Endpoint

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Percentage of Participants With HbA1c <7% at Month 6 Endpoint

    Time frame: Month 6

  2. Percentage of Participants With HbA1c Less Than or Equal to 6.5% at Month 6 Endpoint

    Time frame: Month 6

  3. Change In Average Pre-Injection Self-Monitored Plasma Glucose (SMPG) From Baseline Month 6 Endpoint

    Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Average was assessed by the mean of at least 3 SMPG calculated over the 7 days preceding the assessment visit.

    Time frame: Baseline, Month 6

  4. Change in Variability of Pre-injection SMPG From Baseline to Month 6 Endpoint

    Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Variability was assessed by the mean of coefficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 3 SMPG measured during the 7 days preceding the assessment visit.

    Time frame: Baseline, Month 6

  5. Change in Fasting Plasma Glucose From Baseline to Month 6 Endpoint

    Time frame: Baseline, Month 6

  6. Percentage of Participants With Fasting Plasma Glucose (FPG) <5.6 mmol/L (100 mg/dL) At Month 6

    Time frame: Month 6

  7. Percentage of Participants With FPG <7.2 mmol/L (130 mg/dL) at Month 6 Endpoint

    Time frame: Month 6

  8. Change in 8--Point SMPG Profiles Per Time Point From Baseline to Month 6 Endpoint

    Change in each time-point of 8-point SMPG profile: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime.

    Time frame: Baseline, Month 6

  9. Change in Daily Average Total Insulin Dose From Baseline to Month 6 Endpoint

    Time frame: Baseline, Month 6

  10. Change in Total Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint

    DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1 and 4-8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction.

    Time frame: Baseline, Month 6

  11. Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12

    Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of \<=3.9 mmol/L \[70 mg/dL\]); Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level \<=3.9 mmol/L); Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level \<=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose); Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level \>3.9 mmol/L); Severe and/or confirmed a hypoglycemia (plasma glucose \<=3.9 mmol/L).

    Time frame: Up to Month 12

07

Results

Posted Apr 23, 2015

Participant flow

A total of 846 participants were screened, of whom 297 participants were screen failure and 549 participants were randomized.

Participant flow — Overall Study
MilestoneHOE901--U300Lantus
Started274275
Modified intent-to-treat population273273
Completed219225
Not completed5550
Withdrew: Adverse event54
Withdrew: Lack of efficacy52
Withdrew: Protocol violation136
Withdrew: Personal reason1725
Withdrew: Selection criterion / protocol violation75
Withdrew: Lost to follow-up50
Withdrew: Site closure / site withdrawal13
Withdrew: Nonserious hypoglycemia03
Withdrew: Perceived lack of efficacy11
Withdrew: Possibly hypoglycemia10
Withdrew: Serious adverse event of hypoglycemia01

Outcome measures

PrimaryChange In HbA1c From Baseline to Month 6 Endpoint
Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percentage of hemoglobin
Change In HbA1c From Baseline to Month 6 Endpoint
percentage of hemoglobinHOE901--U300Lantus
Change In HbA1c From Baseline to Month 6 Endpoint-0.40 ± 0.051-0.44 ± 0.051
Statistical analysis
  • HOE901--U300 vs Lantus · Least squares (ls) mean difference: 0.04 · 95% CI -0.098 to 0.185
SecondaryPercentage of Participants With HbA1c <7% at Month 6 Endpoint
Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c <7% at Month 6 Endpoint
percentage of participantsHOE901--U300Lantus
Percentage of Participants With HbA1c <7% at Month 6 Endpoint16.815.0
SecondaryPercentage of Participants With HbA1c Less Than or Equal to 6.5% at Month 6 Endpoint
Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With HbA1c Less Than or Equal to 6.5% at Month 6 Endpoint
percentage of participantsHOE901--U300Lantus
Percentage of Participants With HbA1c Less Than or Equal to 6.5% at Month 6 Endpoint8.15.5
SecondaryChange In Average Pre-Injection Self-Monitored Plasma Glucose (SMPG) From Baseline Month 6 Endpoint

Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Average was assessed by the mean of at least 3 SMPG calculated over the 7 days preceding the assessment visit.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · millimole per liter (mmol/L)
Change In Average Pre-Injection Self-Monitored Plasma Glucose (SMPG) From Baseline Month 6 Endpoint
millimole per liter (mmol/L)HOE901--U300Lantus
Change In Average Pre-Injection Self-Monitored Plasma Glucose (SMPG) From Baseline Month 6 Endpoint-1.16 ± 0.223-0.82 ± 0.233
Statistical analysis
  • HOE901--U300 vs Lantus · Ls mean difference: -0.35 · 95% CI -0.982 to 0.287
SecondaryChange in Variability of Pre-injection SMPG From Baseline to Month 6 Endpoint

Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Variability was assessed by the mean of coefficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 3 SMPG measured during the 7 days preceding the assessment visit.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · percentage of mean
Change in Variability of Pre-injection SMPG From Baseline to Month 6 Endpoint
percentage of meanHOE901--U300Lantus
Change in Variability of Pre-injection SMPG From Baseline to Month 6 Endpoint-3.03 ± 1.573-1.76 ± 1.651
SecondaryChange in Fasting Plasma Glucose From Baseline to Month 6 Endpoint
Time frame:
Baseline, Month 6
Reported as:
Least squares mean · mmol/L
Change in Fasting Plasma Glucose From Baseline to Month 6 Endpoint
mmol/LHOE901--U300Lantus
Change in Fasting Plasma Glucose From Baseline to Month 6 Endpoint-0.95 ± 0.263-1.14 ± 0.260
SecondaryPercentage of Participants With Fasting Plasma Glucose (FPG) <5.6 mmol/L (100 mg/dL) At Month 6
Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With Fasting Plasma Glucose (FPG) <5.6 mmol/L (100 mg/dL) At Month 6
percentage of participantsHOE901--U300Lantus
Percentage of Participants With Fasting Plasma Glucose (FPG) <5.6 mmol/L (100 mg/dL) At Month 69.912.8
SecondaryPercentage of Participants With FPG <7.2 mmol/L (130 mg/dL) at Month 6 Endpoint
Time frame:
Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With FPG <7.2 mmol/L (130 mg/dL) at Month 6 Endpoint
percentage of participantsHOE901--U300Lantus
Percentage of Participants With FPG <7.2 mmol/L (130 mg/dL) at Month 6 Endpoint25.325.6
SecondaryChange in 8--Point SMPG Profiles Per Time Point From Baseline to Month 6 Endpoint

Change in each time-point of 8-point SMPG profile: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime.

Time frame:
Baseline, Month 6
Reported as:
Mean · mmol/L
Change in 8--Point SMPG Profiles Per Time Point From Baseline to Month 6 Endpoint
mmol/LHOE901--U300Lantus
03:00 at Night (n= 156, 159)-0.47 ± 4.56-0.67 ± 4.98
Pre--Breakfast (n= 166, 167)-0.86 ± 5.30-0.07 ± 5.20
2 Hours After Breakfast (n= 152, 156)-0.62 ± 4.75-1.18 ± 5.66
Pre--Lunch (n= 166, 166)-0.95 ± 4.53-0.93 ± 4.76
2 Hours After Lunch (n= 163,163)-0.13 ± 5.20-1.43 ± 5.37
Pre--Dinner (n= 165,166)-0.56 ± 6.00-1.74 ± 5.28
2 Hours After Dinner (n= 154,152)-0.93 ± 5.27-1.19 ± 5.51
Bedtime (n= 141,146)-0.80 ± 5.39-1.91 ± 5.10
SecondaryChange in Daily Average Total Insulin Dose From Baseline to Month 6 Endpoint
Time frame:
Baseline, Month 6
Reported as:
Mean · U/kg
Change in Daily Average Total Insulin Dose From Baseline to Month 6 Endpoint
U/kgHOE901--U300Lantus
Change in Daily Average Total Insulin Dose From Baseline to Month 6 Endpoint0.19 ± 0.220.10 ± 0.16
SecondaryChange in Total Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint

DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1 and 4-8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction.

Time frame:
Baseline, Month 6
Reported as:
Least squares mean · units on a scale
Change in Total Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint
units on a scaleHOE901--U300Lantus
Change in Total Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint1.00 ± 0.3311.41 ± 0.334
SecondaryPercentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12

Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of \<=3.9 mmol/L \[70 mg/dL\]); Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level \<=3.9 mmol/L); Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level \<=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose); Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level \>3.9 mmol/L); Severe and/or confirmed a hypoglycemia (plasma glucose \<=3.9 mmol/L).

Time frame:
Up to Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12
percentage of participantsHOE901--U300Lantus
Any Hypoglycemia Event: All Hypoglycemia95.394.9
Severe Hypoglycemia: All Hypoglycemia9.111.3
Documented Symptomatic: All Hypoglycemia87.686.5
Asymptomatic: All Hypoglycemia76.681.5
Probable Symptomatic: All Hypoglycemia11.315.3
Relative: All Hypoglycemia14.69.5
Severe and/or Confirmed: All Hypoglycemia94.994.5
Any Hypoglycemia Event: Nocturnal Hypoglycemia73.474.9
Severe Hypoglycemia: Nocturnal Hypoglycemia3.33.3
Documented Symptomatic: Nocturnal Hypoglycemia64.263.3
Asymptomatic: Nocturnal Hypoglycemia35.038.9
Probable Symptomatic: Nocturnal Hypoglycemia5.16.5
Relative: Nocturnal Hypoglycemia4.05.5
Severe and/or Confirmed: Nocturnal Hypoglycemia72.674.5

Adverse events

Collected over All Adverse Events (AE) were collected from signature of informed consent form up to study completion regardless of seriousness or relationship to study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HOE901--U300—27/274 (9.9%)113/274 (41.2%)
Lantus—26/275 (9.5%)86/275 (31.3%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventHOE901--U300Lantus
HypoglycaemiaMetabolism and nutrition disorders16/27413/275
Diabetic ketoacidosisMetabolism and nutrition disorders2/2741/275
Road traffic accidentInjury, poisoning and procedural complications1/2742/275
Atrioventricular block completeCardiac disorders1/2740/275
Coronary artery diseaseCardiac disorders1/2740/275
HypersensitivityImmune system disorders1/2740/275
CellulitisInfections and infestations1/2740/275
ErysipelasInfections and infestations1/2740/275
H1N1 influenzaInfections and infestations1/2740/275
PyelonephritisInfections and infestations1/2740/275
Most frequent other events
Most frequent other events
EventHOE901--U300Lantus
NasopharyngitisInfections and infestations43/27435/275
Upper respiratory tract infectionInfections and infestations38/27426/275
HeadacheNervous system disorders17/27413/275
InfluenzaInfections and infestations16/27414/275
SinusitisInfections and infestations14/27411/275
Back painMusculoskeletal and connective tissue disorders14/2747/275

Baseline characteristics

Randomized population: all screened participants (who originally met inclusion criteria and signed informed consent) allocated to a treatment group and recorded in Interactive Voice/Web Response System (IVRS/IWRS) database, regardless of whether treatment was used or not. Participants were analyzed in treatment group to which they were randomized.

Age, Continuous
Age, Continuous(years)HOE901--U300LantusTotal
Mean46.4 ± 13.948.2 ± 13.447.3 ± 13.7
Sex: Female, Male
Sex: Female, Male(Participants)HOE901--U300LantusTotal
Female125111236
Male149164313
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))HOE901--U300LantusTotal
Mean27.6 ± 5.527.6 ± 4.727.6 ± 5.1
Duration of Diabetes
Duration of Diabetes(years)HOE901--U300LantusTotal
Mean20.5 ± 12.721.4 ± 13.121.0 ± 12.9
Glycated Hemoglobin (HbA1c)
Glycated Hemoglobin (HbA1c)(participants)HOE901--U300LantusTotal
Less Than (<) 8%105105210
Greater Than or Equal to (>=) 8%169170339
Basal Insulin Daily Dose
Basal Insulin Daily Dose(units per kilogram (U/kg))HOE901--U300LantusTotal
Mean0.381 ± 0.1730.372 ± 0.1520.376 ± 0.162
Total Insulin Daily Dose
Total Insulin Daily Dose(U/kg)HOE901--U300LantusTotal
Mean0.714 ± 0.2780.724 ± 0.2450.719 ± 0.262
08

Study locations

147 sites
  • Investigational Site Number 840156
    Chandler, Arizona 85224, United States
  • Investigational Site Number 840177
    Little Rock, Arkansas 72205, United States
  • Investigational Site Number 840430
    Bell Gardens, California 90201, United States
  • Investigational Site Number 840131
    Escondido, California 92025, United States
  • Investigational Site Number 840140
    Fresno, California 93720, United States
  • Investigational Site Number 840107
    Greenbrae, California 94904, United States
  • Investigational Site Number 840149
    Huntington Beach, California 92648, United States
  • Investigational Site Number 840120
    La Jolla, California 92037, United States
  • Investigational Site Number 840123
    La Mesa, California 91942, United States
  • Investigational Site Number 840159
    La Mesa, California 91942, United States
  • Investigational Site Number 840114
    Long Beach, California 90806, United States
  • Investigational Site Number 840189
    Mission Hills, California 91345, United States
  • Investigational Site Number 840105
    Temecula, California 92591, United States
  • Investigational Site Number 840155
    Tustin, California 92780, United States
  • Investigational Site Number 840115
    Walnut Creek, California 94598, United States
  • Investigational Site Number 840160
    Denver, Colorado 80239, United States
  • Investigational Site Number 840188
    Denver, Colorado 80262, United States
  • Investigational Site Number 840196
    New Haven, Connecticut 06520, United States
  • Investigational Site Number 840113
    Bradenton, Florida 34208, United States
  • Investigational Site Number 840102
    Hialeah, Florida 33012, United States
  • Investigational Site Number 840134
    Hollywood, Florida 33021, United States
  • Investigational Site Number 840185
    Jacksonville, Florida 32216, United States
  • Investigational Site Number 840116
    Jacksonville, Florida 32258, United States
  • Investigational Site Number 840126
    Miami, Florida 33144, United States
  • Investigational Site Number 840179
    Miami, Florida 33176, United States
  • Investigational Site Number 840117
    New Port Richey, Florida 34652, United States
  • Investigational Site Number 840174
    Orlando, Florida 32806, United States
  • Investigational Site Number 840110
    Oviedo, Florida 32765, United States
  • Investigational Site Number 840178
    Palm Harbor, Florida 34684, United States
  • Investigational Site Number 840181
    Tampa, Florida 33613, United States
  • Investigational Site Number 840420
    West Palm Beach, Florida 33401, United States
  • Investigational Site Number 840195
    Atlanta, Georgia 30318, United States
  • Investigational Site Number 840124
    Honolulu, Hawaii 96814, United States
  • Investigational Site Number 840167
    Idaho Falls, Idaho 83404, United States
  • Investigational Site Number 840163
    Nampa, Idaho 83686, United States
  • Investigational Site Number 840162
    Springfield, Illinois 62704, United States
  • Investigational Site Number 840172
    Avon, Indiana 46123, United States
  • Investigational Site Number 840197
    Indianapolis, Indiana 46202, United States
  • Investigational Site Number 840108
    Des Moines, Iowa 50314, United States
  • Investigational Site Number 840407
    Iowa City, Iowa, United States
  • Investigational Site Number 840170
    Topeka, Kansas 66606, United States
  • Investigational Site Number 840421
    Lexington, Kentucky 40503, United States
  • Investigational Site Number 840426
    Metairie, Louisiana 70006, United States
  • Investigational Site Number 840104
    Baltimore, Maryland 21237, United States
  • Investigational Site Number 840180
    Rockville, Maryland 20852, United States
  • Investigational Site Number 840137
    Haverhill, Massachusetts 1830, United States
  • Investigational Site Number 840408
    Detroit, Michigan 48202, United States
  • Investigational Site Number 840153
    Madison Heights, Michigan 48071, United States
  • Investigational Site Number 840171
    St Louis Park, Minnesota 55416, United States
  • Investigational Site Number 840184
    St Louis, Missouri 63110, United States
  • Investigational Site Number 840106
    Omaha, Nebraska 68131, United States
  • Investigational Site Number 840145
    Omaha, Nebraska 68131, United States
  • Investigational Site Number 840139
    Las Vegas, Nevada 89148, United States
  • Investigational Site Number 840151
    Albuquerque, New Mexico 87106, United States
  • Investigational Site Number 840191
    New Hyde Park, New York 11042, United States
  • Investigational Site Number 840173
    Syracuse, New York 13210, United States
  • Investigational Site Number 840133
    Asheville, North Carolina 28803, United States
  • Investigational Site Number 840175
    Chapel Hill, North Carolina 27599-7295, United States
  • Investigational Site Number 840161
    Morganton, North Carolina 28655, United States
  • Investigational Site Number 840169
    Mentor, Ohio 44060, United States
  • Investigational Site Number 840119
    Norman, Oklahoma 73069, United States
  • Investigational Site Number 840112
    Bend, Oregon 97701, United States
  • Investigational Site Number 840136
    Greer, South Carolina 29651, United States
  • Investigational Site Number 840122
    Dakota Dunes, South Dakota 57049, United States
  • Investigational Site Number 840144
    Chattanooga, Tennessee 37404, United States
  • Investigational Site Number 840187
    Nashville, Tennessee 37232, United States
  • Investigational Site Number 840109
    Austin, Texas 78731, United States
  • Investigational Site Number 840157
    Austin, Texas 78731, United States
  • Investigational Site Number 840150
    Dallas, Texas 75230, United States
  • Investigational Site Number 840412
    Dallas, Texas 75231, United States
  • Investigational Site Number 840130
    Houston, Texas 77030, United States
  • Investigational Site Number 840141
    Houston, Texas 77095, United States
  • Investigational Site Number 840166
    San Antonio, Texas 78229, United States
  • Investigational Site Number 840101
    Murray, Utah 84123, United States
  • Investigational Site Number 840125
    Burke, Virginia 22015, United States
  • Investigational Site Number 840427
    Chesapeake, Virginia 23321, United States
  • Investigational Site Number 840103
    Manassas, Virginia 20110, United States
  • Investigational Site Number 840132
    Renton, Washington 98055, United States
  • Investigational Site Number 840403
    Seattle, Washington 98195, United States
  • Investigational Site Number 840402
    Spokane, Washington 99220, United States
  • Investigational Site Number 840127
    Tacoma, Washington 98415-0299, United States
  • Investigational Site Number 840411
    Milwaukee, Wisconsin 53209-0996, United States
  • Investigational Site Number 124110
    Coquitlam, V3K 3P4, Canada
  • Investigational Site Number 124104
    Laval, H7T 2P5, Canada
  • Investigational Site Number 124108
    Mirabel, J7J 2K8, Canada
  • Investigational Site Number 124109
    Montreal, H1Y 3L1, Canada
  • Investigational Site Number 124105
    Thornhill, L4J 8L7, Canada
  • Investigational Site Number 124101
    Toronto, M4R 2G4, Canada
  • Investigational Site Number 203102
    Brno, 62500, Czech Republic
  • Investigational Site Number 203104
    Praha 10, 10034, Czech Republic
  • Investigational Site Number 203103
    Praha 8, 18100, Czech Republic
  • Investigational Site Number 208103
    Esbjerg, 6700, Denmark
  • Investigational Site Number 208105
    Gentofte, 2900, Denmark
  • Investigational Site Number 208104
    København Nv, 2400, Denmark
  • Investigational Site Number 208107
    Køge, 4600, Denmark
  • Investigational Site Number 208102
    Ålborg, 9100, Denmark
  • Investigational Site Number 233104
    Pärnu, 80018, Estonia
  • Investigational Site Number 233105
    Tallinn, 13419, Estonia
  • Investigational Site Number 233106
    Tartu, 50406, Estonia
  • Investigational Site Number 233101
    Tartu, 50410, Estonia

Showing the first 100 of 147 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC. Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4). Diabetes Obes Metab. 2018 Jan;20(1):121-128. doi: 10.1111/dom.13048. Epub 2017 Aug 8. PubMed 28661585 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Sep 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year 7 months after primary completion. A results delay was requested in Nov 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2012
First posted
Sep 11, 2012
Start
Sep 2012
Primary completionActual
Sep 2013
CompletionActual
Mar 2014
Results delay requested
Nov 14, 2014
Results first posted
Apr 23, 2015
Last update
Jun 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01683266
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 11, 2012
Start date
Sep 2012
Primary completion
Sep 2013
Completion
Mar 2014
Results posted
Apr 23, 2015
Last update
Jun 24, 2015

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion